Skip to main content
Sheldon Preskorn, MD, Psychiatry, Wichita, KS

SheldonHPreskornMD

Psychiatry Wichita, KS

Geriatric Psychiatry, Pain Medicine

Professor, Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine

Are you Dr. Preskorn?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 60 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    1001 N Minneapolis
    Wichita, KS 67214
    Phone+1 316-293-2647
    Fax+1 316-293-1863

Summary

  • Dr. Sheldon Preskorn, MD is a board certified psychiatrist in Wichita, Kansas. He is currently licensed to practice medicine in Kansas, Oklahoma, and Missouri. He is affiliated with Ascension Via Christi St. Francis and is a Professor at University of Kansas School of Medicine.

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Psychiatry, 1976 - 1978
  • University of Kansas School of Medicine
    University of Kansas School of MedicineInternship, Transitional Year, 1975 - 1976
  • University of Kansas School of Medicine
    University of Kansas School of MedicineResidency, Pathology-Anatomic and Clinical, 1973 - 1974
  • University of Kansas School of Medicine
    University of Kansas School of MedicineClass of 1974

Certifications & Licensure

  • KS State Medical License
    KS State Medical License 1975 - 2025
  • OK State Medical License
    OK State Medical License 2013 - 2016
  • MO State Medical License
    MO State Medical License 1976 - 2014
  • American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

Press Mentions

  • BioXcel Therapeutics to Highlight Advances in the BXCL501 Program at 2019 Investor Event in New York City
    BioXcel Therapeutics to Highlight Advances in the BXCL501 Program at 2019 Investor Event in New York CityMay 13th, 2019
  • Antidepressant Trials Exclude Vast Majority of Depressed Patients
    Antidepressant Trials Exclude Vast Majority of Depressed PatientsJuly 15th, 2015

Grant Support

  • Central Adrenergic System And Blood Brain BarrierNational Institute Of Neurological Disorders And Stroke1985–1986